PGDx is excited to announce we’ve expanded PlasmaSELECT 64 to add microsatellite instability analyses. Called PlasmaSELECT 64 + MSI, it is now the only pan-cancer assay for tumor profiling that can also evaluate MSI status in plasma.
PlasmaSELECT 64 identifies clinically actionable and functionally important sequence mutations and structural alterations across multiple cancer types using patient blood or plasma, without the need for invasive tissue biopsies. And now as the first liquid biopsy tumor profiling assay with the ability to test for MSI, it becomes an even more powerful and valuable immuno-oncology tool.
Analyzing MSI for high tumor mutational load helps identify cancer patients who might benefit from particular immuno-oncology cancer therapies. MSI status as a biomarker for mutational load is important because studies have shown that patients whose tumors have a large number of mutations, or high mutational load, are also likely to harbor new tumor-specific antigens that can help stimulate a robust anti-cancer immune response. These patients are more likely than those with fewer mutations to respond to treatment with immunotherapies, including checkpoint inhibitors such as Keytruda® (permbrolizumab) or Opdivo® (nivolumab).
Heretofore, determining tumor mutational load required using DNA from tissue biopsy, which typically is available, if at all, only at the start of treatment. But now PlasmaSELECT 64 + MSI allows liquid biopsy of cell-free tumor DNA present in a patient’s blood or plasma, making it possible to track changes in mutational status as treatment proceeds.
“We are proud to launch this revolutionary expansion just six months after we introduced PlasmaSELECT 64 as the most accurate, clinically actionable liquid biopsy tumor profiling assay available,” said Doug Ward, CEO of PGDx. “The ability to generate DNA tumor profiling noninvasively using blood or plasma offers many advantages and makes genomic testing more accessible and usable. Our leadership in making MSI testing available in this format is another example of PGDx’s commitment to staying at the forefront of cancer genomic testing.”